# A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

> **NCT04537806** · PHASE3 · TERMINATED · sponsor: **Sage Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Acute Respiratory Distress Syndrome
- COVID-19

## Interventions

- **DRUG:** Brexanolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04537806
- **Lead sponsor:** Sage Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-18
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Internal company decision
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537806, "A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04537806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*